COMPANY
Lumicell, Inc.
FDA-cleared device company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Commercial Marketing Manager | Waltham, Massachusetts | Not stated | Oct 21, 2026 |
| Account Executive | Houston, Texas, United States | Not stated | Oct 11, 2026 |
Timeline
- Trial start —: Post-market Evaluation of LumiSystem: Intraoperative Margin Performance and Clinical Utility (IMPACT) Registry source ↗
- Trial start —: Post-market Safety Study of LUMISIGHT source ↗
- Trial start Not phased (device or behavioral study): Feasibility Study of LUM Imaging System for Pancreatic Cancer source ↗
- Partnership Partnership / licensing announced Dec 18, 2025. Source: company's own press page. source ↗
- Trial start Phase 2: Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients source ↗
- Trial start Phase 3: Investigation of Novel Surgical Imaging for Tumor Excision source ↗
- Trial start Not phased (device or behavioral study): Feasibility of the LUM Imaging System for Detection of Cancer to the Brain source ↗
- Trial start Phase 1/Phase 2: Feasibility of the LUM Imaging System for Detection of Prostate Cancer source ↗
- Trial start Phase 1/Phase 2: Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies source ↗
- Trial start Phase 2: Intraoperative Detection of Residual Cancer in Breast Cancer source ↗
- Trial start Phase 1/Phase 2: Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers source ↗
- Trial start Phase 1/Phase 2: Feasibility Study of Intraoperative Imaging in Breast Cancer source ↗
Upcoming milestones
- 2026-12 (ESTIMATED) · Phase 1/Phase 2 · Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers · NCT02584244
- 2030-12 (ESTIMATED) · · Post-market Evaluation of LumiSystem: Intraoperative Margin Performance and Clinical Utility (IMPACT) Registry · NCT07616856
- 2030-12 (ESTIMATED) · · Post-market Safety Study of LUMISIGHT · NCT07572162
Funding
- Partnership / licensing announced Dec 18, 2025. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 11
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07616856 | Post-market Evaluation of LumiSystem: Intraoperative Margin Performance and Clinical Utility (IMPACT) Registry | Not listed | Not yet recruiting | 2026-07 | 2030-12 (estimated) |
| NCT07572162 | Post-market Safety Study of LUMISIGHT | Not listed | Not yet recruiting | 2026-06 | 2030-12 (estimated) |
| NCT03834272 | Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies | Phase 1/Phase 2 | Completed | Mar 18, 2019 | Aug 19, 2025 (actual) |
| NCT02584244 | Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | Phase 1/Phase 2 | Recruiting | Aug 4, 2016 | 2026-12 (estimated) |
| NCT04440982 | Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients | Phase 2 | Terminated | Sep 1, 2020 | Nov 30, 2023 (actual) |
| NCT03717142 | Feasibility of the LUM Imaging System for Detection of Cancer to the Brain | Not phased (device or behavioral study) | Terminated | May 3, 2019 | Sep 13, 2023 (actual) |
| NCT04276909 | Feasibility Study of LUM Imaging System for Pancreatic Cancer | Not phased (device or behavioral study) | Withdrawn | 2026-01 | 2026-01 (estimated) |
| NCT03686215 | Investigation of Novel Surgical Imaging for Tumor Excision | Phase 3 | Completed | Nov 4, 2019 | Dec 9, 2021 (actual) |
| NCT03321929 | Intraoperative Detection of Residual Cancer in Breast Cancer | Phase 2 | Completed | Feb 6, 2018 | Apr 10, 2020 (actual) |
| NCT02438358 | Feasibility Study of Intraoperative Imaging in Breast Cancer | Phase 1/Phase 2 | Completed | 2015-06 | 2017-09 (actual) |
| NCT03441464 | Feasibility of the LUM Imaging System for Detection of Prostate Cancer | Phase 1/Phase 2 | Terminated | Mar 20, 2019 | Feb 11, 2021 (actual) |
NIH awards 7
- NIH contract (government contract; not a grant and not an investment round) 75N91024C00081-0-9999-1 FY2024: $399,036 awarded for that fiscal year; activity N43 (OTHER_NIH); PI FERRER, JORGE; recipient as written: LUMICELL, INC., Newton, MA. SBIR Topic 463: Cli source ↗
- NIH award 5R44CA211013-02 FY2017: $937,091 awarded for that fiscal year; activity R44 (SBIR); PI LEE, W. DAVID; recipient as written: LUMICELL, INC., Newton, MA. A prospective, multi-center pivotal study of the LUM I source ↗
- NIH award 1R44CA211013-01 FY2016: $1,033,123 awarded for that fiscal year; activity R44 (SBIR); PI LEE, W. DAVID; recipient as written: LUMICELL, INC., Newton, MA. A prospective, multi-center pivotal study of the LUM source ↗
- NIH award 5U44CA165024-03 FY2014: $207,388 awarded for that fiscal year; activity U44 (SBIR); PI LEE, W. DAVID; recipient as written: LUMICELL, INC., Newton, MA. Engineered imaging nanoparticles for real-time detecti source ↗
- NIH award 2U44CA165024-02 FY2013: $630,952 awarded for that fiscal year; activity U44 (SBIR); PI LEE, W. DAVID; recipient as written: LUMICELL, INC., Newton, MA. Engineered imaging nanoparticles for real-time detecti source ↗
- NIH award 1U43CA165024-01 FY2011: $212,752 awarded for that fiscal year; activity U43 (SBIR); PI LEE, W. DAVID; recipient as written: LUMICELL, INC., Newton, MA. Engineered imaging nanoparticle for realtime detection source ↗
- NIH contract (government contract; not a grant and not an investment round) 261201100122C-0-0-1 FY2011: $248,461 awarded for that fiscal year; activity N43 (OTHER_NIH); PI LEE, W. DAVID; recipient as written: LUMICELL, INC., Newton, MA. TAS::75 0849::TAS SBIR source ↗
Open jobs 2
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Commercial Marketing Manager | Waltham, Massachusetts | Not stated | Oct 21, 2026 | Not stated |
| Account Executive | Houston, Texas, United States | Not stated | Oct 11, 2026 | Mid |
Connect
See your connections at Lumicell on LinkedIn (search by name, results not checked)